Remove Medicine Remove Patients Remove Pharmacology
article thumbnail

Alzheimer’s drug requires strengthened pharmacovigilance approach

European Pharmaceutical Review

A paper published by the Drug Safety Research Unit (DSRU) in the British Journal for Clinical Pharmacology , has asserted the need for ongoing assessment of the safety and effectiveness of the Alzheimers drug lecanemab in the real-world clinical setting.

Safety 59
article thumbnail

Tackling the complex development landscape of pain medicines

European Pharmaceutical Review

What are the key current challenges in the development of pain medicines? What is the present clinical landscape for pain management medicines, especially chronic pain? Pain management therapies: Pfizer’s migraine medicine recommended by NICE What are three current development trends for pain management treatments?

Medicine 102
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Pharma Injecting Life into Digital Health Amidst Funding Downturn

MedCity News

Investors in 2022 appeared confident that the continued transformation of drug research and development protocols and the overall life sciences industry will not only include digital health solutions, but will even depend on them for data collection, analysis, patient engagement, and even their therapeutic properties.

Pharma 310
article thumbnail

Why R&D innovation holds the key to greater patient impact

European Pharmaceutical Review

3 With greater scientific understanding of cancer, the industry has made significant progress in developing innovative medicines to help patients. However, access to these medicines is not close to meeting patient demand, creating inequalities in the health prospects of those diagnosed with cancer.

Patients 105
article thumbnail

MHRA Chief Executive to step down

European Pharmaceutical Review

The Chief Executive of the Medicines and Healthcare products Regulatory Agency (MHRA), Dame June Raine, will step down in the Autumn following five years in the role. While she is stepping down from her current role, Dame June shared that she still hopes to contribute “to patient safety and public health in other ways.”

Safety 111
article thumbnail

Cala® Launches The Cala kIQ™ System, Offering Meaningful Tremor Relief for Patients With Essential Tremor and Now Parkinson’s Disease

Legacy MEDSearch

Cala , the bioelectronic medicine leader setting a new standard of care for chronic disease, today announced the commercial launch of its next generation system: the Cala kIQ System, the first and only FDA-cleared wearable device that delivers effective therapy for action hand tremor relief in people with essential tremor and Parkinson’s disease.

article thumbnail

NICE backs use of Boehringer’s Ofev in IPF from diagnosis

pharmaphorum

Thousands more UK patients with idiopathic pulmonary fibrosis (IPF) will now be eligible for treatment with Boehringer Ingelheim’s Ofev, following new guidance from health technology assessment agency NICE. The NHS should make Ofev available within 90 days of the announcement by NICE, which means in mid-March 2023.